IP Library Granted Patent US 8,258,312
Granted Patent B2
US 8,258,312 · App. 12/666,476 · Granted Sep 4, 2012

Process for preparing pure valsartan

Assignee: Mylan Laboratories Ltd
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,258,312
App. No.
12/666,476
Granted
Sep 4, 2012
Kind
B2
Abstract

An improved process for the preparation of substantially pure valsartan employing suitable reagents such as chelating agent and reaction conditions.

Claims (19)

1. A process for the preparation of Valsartan, comprising

a) reacting a compound of formula II:

 with tributyltin azide in a solvent;

b) quenching the reaction with a base;

c) treating the reaction mixture with charcoal and washing with organic solvent;

d) adjusting the pH of the reaction mixture to 6.0-8.0 using an acid and treating with charcoal and filtering;

e) adding a chelating agent to the reaction mixture;

f) adjusting the pH to 3.0-5.0 using an acid;

g) extracting the aqueous layer with an organic solvent;

h) evaporating the solvent to obtain a residue;

i) taking the residue in ethyl acetate and cooling;

j) filtering and drying the precipitates.

2. The process according to claim 1 , wherein the solvent used is xylene, toluene or a mixture thereof.

3. The process according to claim 1 , wherein the base is an alkali metal hydroxide or an alkaline earth metal hydroxide.

4. The process according to claim 3 wherein the base is sodium hydroxide or potassium hydroxide.

5. The process according to claim 1 , wherein the organic solvent is dichloromethane, chloroform or tetrachloromethane.

6. The process according to claim 1 , wherein the acid used is hydrochloric acid.

7. The process according to claim 1 , wherein the chelating agent used is ethylene diamine tetraacetic acid.

8. The process of claim 1 , wherein the Valsartan obtained comprises no more than 5 ppm of a tin-containing compound.

Assignments (4)
CHANGE OF NAME Recorded Jan 12, 2026
From: TIANISH LABORATORIES PRIVATE LIMITED
To: MATRIX PHARMACORP PRIVATE LIMITED
Reel/Frame 074322/0525 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2024
From: MYLAN LABORATORIES LIMITED
To: TIANISH LABORATORIES PRIVATE LIMITED
Reel/Frame 068861/0150 →
CHANGE OF NAME Recorded Jul 9, 2012
From: MATRIX LABORATORIES LIMITTED
To: MYLAN LABORATORIES LIMITED
Reel/Frame 028561/0269 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2010
From: TYAGI, OM DUTT; RAO, JAKKA DEVENDRA; KUMAR, KATUKURI ARAVIND; RAO, DAMMALAPATI VENTAKA LAKSHMI NARASIMHA
To: MATRIX LABORATORIES LTD
Reel/Frame 024025/0991 →
Priority Claims (1)
IN 1383/CHE/2007 · Jun 27, 2007 · national
Continuity (1)
Related Publication 20100197932A1 · Aug 5, 2010